- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04269980
Phentolamine Versus Magnesium Sulphate Infusion During Elective Lumbar Spine Surgery: a Randomized Double Blind Comparative Study
Aperçu de l'étude
Description détaillée
Patients and methods:
This study will be randomized controlled study ( RCT) and will be carried out in Beni-Suef University Hospital after the approval of institutional review board and ethical committee and obtaining a written informed consent from from ASA I and II patients undergoing elective lumbar spine surgery under general anesthesia. The primary outcome will be the achievement of controlled hypotension with MAP of 50-65 mmHg. The secondary outcomes will be blood loss, total dose of hypotensive agents and quality of surgical field.
This study will enroll 30 co-operative ASA physical status I & II patients of both sex aged 20-60 years undergoing elective lumbar spine surgry and study period will be 6 months.
Inclusion criteria:
orthopedic and neurological patients undergoing posterior lumbar spine fusion [American Society of Anesthesiologists (ASA) physical status 1 or 2, operation time of 3 to 5 h and mentally competent.
Exclusion Criteria:
- operation time more than 5 h.
- allergic reaction to drugs.
- Patients with a history of liver, renal, heart and vascular failure, cardiac conduction disturbance.
- opium addiction, any drug or substance abuse and chronic treatment with opium, non-steroidal anti-inflammatory drugs and calcium channel blockers (CCB).
The patients will be blinded to the study drugs and will be randomly assigned into two equal groups by opaque sealed envelope as follows:
Group (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.
Group MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr .
Anaesthetic technique:
On arrival to the operating room, standard monitoring will be established (pulse oximetry, electrocardiography, end-tidal carbon dioxide, and noninvasive arterial blood pressure monitoring), and oxygen will be delivered via a facemask. Two intravenous cannulas will placed; one (22 gauge) in a vein on the dorsum of the hand that the examined drug will be injected in and the other (20 gauge) in the opposite hand.
All patients will receive lactated ringer's solution at approximately 3-5 ml/kg/h perioperatively. The patients will be premedicated with Midazolam 0.05 mg/kg IV 3 minutes before induction. Anesthesia will induced by injecting 2.5 mg/kg propofol, 2 μg/kg fentanyl & 0.5 mg/kg atracurium.
The patients will be ventilated via face mask with 100 % oxygen at a rate of 4 L/min and isoflurane 1.2 %. After 3 minutes, the patients will be intubated using appropriate sized cuffed oral tube lubricated with lidocaine jelly 2 % , After induction of anesthesia, a radial arterial line from the non-dominant hand for continuous monitoring of mean arterial pressure (MAP) will be obtained.
Maintenance of anesthesia will done using isoflurane 1.2 % in 100 % O2. Muscle relaxation will be continued by atracurium 0.1 mg/kg every 20 min. All patients will be mechanically ventilated to maintain end-tidal carbon dioxide between 35-40 mmHg. For 5 minutes, no surgical interventions will be allowed in the subjects to assess target blood pressure.
The MAP will then gradually reduced in both groups to achieve and maintain the target MAP of 50-65 mmHg.
The surgical field will be evaluated by the surgeon using the 0-5 point bleeding scale (0: no bleeding, 1: low bleeding-bleeding does not require aspiration, 2: low bleeding-bleeding requires intermittent aspiration, 3: low bleeding-bleeding requires frequent aspiration, 4: moderate bleeding-bleeding becomes serious when aspirator is withdrawn from the surgical field, 5: serious bleeding-requires persistent aspiration, surgical field impossible) during the intra-operative period (13).
Patients who will develop severe hypotension (MAP <50 mmHg) will be managed by discontinuation of the hypotensive agent and reducing the concentration of isoflurane. If the MAP does not improve, 6 mg Ephedrine will be given IV & these patients will be excluded from the study. Patient who will develop bradycardia (<50 bpm) will be managed by intravenous atropine and will be then excluded from this study.
Infusion of the hypotensive agent will be stopped 5 minutes before the anticipated end of surgery. Any residual neuromuscular block will be antagonized with neostigmine 0.04 mg/kg and atropine 0.02 mg/kg IV.
The patients will be extubated on recovery of adequate tidal volume and sufficient respiratory efforts and transferred to recovery room for observation.
Surgeon's satisfaction will be recorded using the Likert technique or scale at the end of surgery (1 = very dissatisfied to 5 = completely satisfied).
The following data will be recorded :-
- Demographic data of the patients (Age, Sex, BMI) .
- MAP, HR, ETCO2 and SPO2 were recorded immediately prior to induction of anesthesia and subsequently every 5 min till the termination of anesthesia.
- Total phentolamine and magensium doses.
- The quality of surgical field will be evaluated by surgeon using the 0-5 point bleeding scale.
- The amount of blood loss will be determined by collecting the blood and rinsed fluid from the surgical field into the suction bottle by suctioning .The nurse who will not a part of the study made visual assessment of blood soaked gauge pieces that will be consumed during surgery.
- The time needed to reach the target blood pressure.
- Duration of surgery and anesthesia. HB and HTC preoperative and intraoperative Units of blood transfused
- In the recovery room, adverse effects such as nausea, vomiting, agitation, bradycardia, coughing, shivering, reflex tachycardia and rebound hypertension will be recorded.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Banī Suwayf, Egypte
- Recrutement
- Benisuef univercity
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- orthopedic and neurological patients undergoing posterior lumbar spine fusion
- American Society of Anesthesiologists (ASA) physical status 1 or 2,
- operation time of 3 to 5 h
- mentally competent.
Exclusion Criteria:
- operation time more than 5 h.
- allergic reaction to drugs.
- Patients with a history of liver, renal, heart and vascular failure, cardiac conduction disturbance.
- opium addiction, any drug or substance abuse and chronic treatment with opium, non-steroidal anti-inflammatory drugs and calcium channel blockers (CCB).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Group (PHN)
Group (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure
|
MAP
|
|
Comparateur actif: Group MG
Group MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr .
|
MAP
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
mean blood presure
Délai: intraopertaive
|
intraopertaive
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- FMBSUREC/090222020/Ali
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .